Contrasting of Crinetics Pharmaceuticals Inc. (CRNX) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Since Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of both companies.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 2.43M 232.62 27.11M -0.91 0.00
Vertex Pharmaceuticals Incorporated 3.05B 15.33 2.10B 2.07 91.94

Table 1 highlights Crinetics Pharmaceuticals Inc. and Vertex Pharmaceuticals Incorporated’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Crinetics Pharmaceuticals Inc. and Vertex Pharmaceuticals Incorporated.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. -1,115.64% 0% 0%
Vertex Pharmaceuticals Incorporated 68.85% 67.5% 43.8%

Liquidity

Crinetics Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 31 and 31 respectively. The Current Ratio and Quick Ratio of its competitor Vertex Pharmaceuticals Incorporated are 3.4 and 3.3 respectively. Crinetics Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Vertex Pharmaceuticals Incorporated.

Analyst Recommendations

Ratings and Recommendations for Crinetics Pharmaceuticals Inc. and Vertex Pharmaceuticals Incorporated can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Crinetics Pharmaceuticals Inc. 0 0 1 3.00
Vertex Pharmaceuticals Incorporated 0 2 8 2.80

Crinetics Pharmaceuticals Inc. has a 70.65% upside potential and an average price target of $40. Vertex Pharmaceuticals Incorporated on the other hand boasts of a $210 consensus price target and a 14.89% potential upside. The data from earlier shows that analysts opinion suggest that Crinetics Pharmaceuticals Inc. seems more appealing than Vertex Pharmaceuticals Incorporated.

Institutional & Insider Ownership

Roughly 98.6% of Crinetics Pharmaceuticals Inc. shares are owned by institutional investors while 98.1% of Vertex Pharmaceuticals Incorporated are owned by institutional investors. 5.66% are Crinetics Pharmaceuticals Inc.’s share owned by insiders. Competitively, 0.1% are Vertex Pharmaceuticals Incorporated’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. 2.61% -8.83% -31.68% -22.38% 0% -20.11%
Vertex Pharmaceuticals Incorporated 1.99% -0.46% 6.54% 2.8% 14.6% 14.68%

For the past year Crinetics Pharmaceuticals Inc. had bearish trend while Vertex Pharmaceuticals Incorporated had bullish trend.

Summary

Vertex Pharmaceuticals Incorporated beats on 9 of the 13 factors Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.